Edwards reports strong 2025 despite Q4 EPS miss
Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.
11 February 2026
11 February 2026
Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.